CCM
HLVX

Coldstream Capital Management’s HilleVax HLVX Stock Holding History

Coldstream Capital Management’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-187
Closed -$272 – 2078
2025
Q1 		$272 Buy
+187
New +$346 ﹤0.01% 3455

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Coldstream Capital Management's HLVX Position: Q2 2025 in Review

Coldstream Capital Management sold out of HilleVax (HLVX) in Q2 2025, closing a stake of 187 shares — an estimated $272 sold.

Coldstream Capital Management first reported a position in HLVX in Q1 2025 and held it in 1 quarter. The position peaked at $272 in Q1 2025. 74 funds tracked by Wall St. Rank hold HLVX as of Q2 2025.

  • Coldstream Capital Management reported no remaining HilleVax position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 187 HilleVax shares in Q2 2025, an estimated $272.
  • Coldstream Capital Management first reported a position in HilleVax in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's HilleVax position peaked at $272 in Q1 2025.
  • 74 funds tracked by Wall St. Rank held HilleVax as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.